Voyager Therapeutics, Inc. VYGR

2.68 (0.12) (4.29%) as of 25 Sep
Market cap
$172.5M
P/E
0.0×

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
196.45 266.68 230.88 118.85 132.54 181.14 281.53 155.81 169.05 174.42
Receivables
1.91 2.18 83.49 0.26 0.73 8.01 18.50 0.20 1.45 2.30
Total current assets
202.69 276.81 319.68 124.50 136.70 197.77 304.66 162.48 171.79 178.79
Property, Plant, Equpment (Net)
13.14 14.31 16.49 17.86 21.92 25.44 17.99 12.77 10.28 7.89
Long-Term Investments
5.24 65.70 — 1.52 1.78 1.78 1.92 0.63 1.10 1.36
Long-term assets (Other)
2.74 2.87 1.59 1.52 1.78 2.32 1.72 1.15 1.30 1.53
Total non-current assets
49.59 116.24 31.60 34.86 57.16 63.82 50.10 14.55 12.69 10.78
Total Assets
252.28 393.05 351.28 159.36 193.86 261.58 354.76 177.03 184.48 189.57
Accounts Payable
5.01 4.00 1.60 2.57 0.57 0.63 4.07 1.04 1.02 0.55
Accrued Expenses
12.10 14.17 16.82 7.82 10.95 14.21 21.52 9.79 11.50 6.49
Current Revenue (Deferred)
1.59 24.39 42.88 59.38 33.89 7.73 47.23 20.85 3.38 6.76
Other current liabilities
— 7.23 3.20 2.83 5.57 4.20 3.19 30.64 14.88 13.25
Total current liabilities
26.54 49.79 64.51 72.59 50.98 26.77 76.01 31.67 15.90 13.80
Non-current Revenue (Deferred)
— 6.00 32.36 6.45 8.21 36.09 147.26 92.20 33.52 39.82
Non-current Liabilities (Other)
1.00 1.00 1.00 21.30 39.61 44.41 31.98 6.71 1.01 0.03
Total non-current liabilities
29.66 43.50 50.45 27.75 47.82 80.50 179.24 98.91 34.53 39.84
Total liabilities
56.20 93.29 114.96 100.34 98.80 107.26 255.25 130.58 50.43 53.64
Additional Paid In Capital
641.90 626.30 497.51 452.71 442.26 430.32 412.23 315.60 295.02 225.96
Common Stock (Net)
0.06 0.06 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03
Retained Earnings
(445.90) (326.18) (261.18) (393.51) (347.10) (275.91) (312.65) (269.05) (160.71) (90.01)
Common Equity (Total)
196.08 299.76 236.32 59.02 95.06 154.32 99.51 46.45 134.05 135.92
Shareholders Equity (Total)
196.08 299.76 236.32 59.02 95.06 154.32 99.51 46.45 134.05 135.92
Shareholders Equity and Liabilities (Total)
252.28 393.05 351.28 159.36 193.86 261.58 354.76 177.03 184.48 189.57
Shares (Common)
59.05 54.73 44.04 38.61 37.92 37.37 36.87 32.37 31.57 25.60
Shareholders Equity (Tangible)
196.08 299.76 236.32 59.02 95.06 154.32 99.51 46.45 134.05 135.92
Net Debt
(196.45) (266.68) (230.87) (118.85) (132.54) (181.14) (281.53) (155.81) (169.05) (174.42)
Total Debt
— — — 23.13 44.18 47.61 34.17 — — —

Fold the line items

In millions of $ except per-share values · columns are period end dates